Breast cancer patients with low ENPP1 expression have hot tumors and responded completely to pembrolizumab with 7-y metastasis-free survival, demonstrating ENPP1 levels can be used as a biomarker for patient stratification and should also be targeted for immunotherapy. The gene discussed is ENPP1; the disease is breast cancer.